NDA 203469 · Takeda Pharms USA
Iclusig
Ponatinib Hydrochloride · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 14, 2012
Approved uses
7
Original approval plus efficacy supplements
Registered trials
67
8 Phase 3, 13 recruiting
FAERS reports
0
4,483 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY See full prescribing information for complete boxed warning. Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG. ( 2.2 , 5.1 ) Venous thromboembolic events (VTEs) have occurred in...
What it is approved for
From the label in effect Aug 14, 2026.
ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or...
Mechanism: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC 50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR::ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2025 Supplement 38 · Efficacy OrphanLabelMedication GuideLetter
- Mar 19, 2024 Supplement 37 · Efficacy · priority review OrphanLabelLetter
- Feb 15, 2022 Supplement 35 · Efficacy OrphanLetterLabel
- Dec 18, 2020 Supplement 34 · Efficacy · priority review OrphanLabelLetter
- Nov 28, 2016 Supplement 22 · Efficacy OrphanLetterLabel
- Jun 2, 2016 Supplement 21 · Efficacy OrphanLabelLetter
- Dec 14, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewOther Important Information from FDASummary Review
4 products under this application
- ICLUSIG · PONATINIB HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription
- ICLUSIG · PONATINIB HYDROCHLORIDE EQ 45MG BASE · TABLET, ORAL · Prescription
- ICLUSIG · PONATINIB HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
- ICLUSIG · PONATINIB HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ponatinib" as an intervention, any sponsor and status, largest first.
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06860269 · 1,200 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2035
Drug: Randomization + Blinatumomab + chemotherapy; Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone and 1 more · For: Acute Lymphoblastic Leukemia
Sites: Paris, France
- Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)Pivotal-lookingCompleted
Ariad PharmaceuticalsTakeda (TAK)
NCT01207440 · 449 participants · Start Sep 30, 2010 · Primary completion Dec 20, 2018
Drug: Ponatinib · For: Chronic Myeloid Leukemia; Ph+ Acute Lymphoblastic Leukemia
Sites: St Leonards, Australia; Woolloongabba, Australia; Adelaide, Australia · 42 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT04530565 · 348 participants (planned) · Start Jan 25, 2021 · Primary completion Jul 1, 2028
Drug: Blinatumomab; Cyclophosphamide and 9 more · For: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Sites: Birmingham, Alabama; Anchorage, Alaska; Fort Smith, Arkansas · 211 sites in all
- Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Pivotal-lookingTerminated
Ariad PharmaceuticalsTakeda (TAK)
NCT01650805 · 307 participants · Start Jun 2012 · Primary completion Oct 2013
Drug: ponatinib; imatinib (Gleevec/ Glivec) · For: Chronic Myeloid Leukemia
Sites: Burbank, California; Los Angeles, California; Pleasant Hill, California · 170 sites in all
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02467270 · 283 participants · Start Jul 13, 2015 · Primary completion Apr 29, 2020
Drug: Ponatinib · For: Myeloid Leukemia, Chronic, Chronic Phase
Sites: Atlanta, Georgia; Indianapolis, Indiana; Baltimore, Maryland · 86 sites in all
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT03589326 · 245 participants · Start Oct 4, 2018 · Primary completion Aug 12, 2022
Drug: Ponatinib; Imatinib and 5 more · For: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 92 sites in all
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLPivotal-lookingActive, not recruiting
Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
NCT04722848 · 236 participants · Start Sep 8, 2021 · Primary completion Sep 2027
Drug: Ponatinib + Blinatumomab; Chemotherapy + Imatinib · For: Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); ALL, Adult; Philadelphia-Positive ALL
Sites: Ascoli Piceno, Italy; Bari, Italy; Bergamo, Italy · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death756
- off label use350
- rash272
- headache268
- fatigue260
- pyrexia255
- neoplasm progression197
- drug ineffective195
- hypertension195
- nausea195
- constipation192
- platelet count decreased166
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Iclusig (Ponatinib HCl)
2024 spending
$160M
Beneficiaries
1,065
7,555 claims
Per beneficiary
$149,795
$698.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $83,013,331 |
| 2021 | $89,035,994 |
| 2022 | $100,843,138 |
| 2023 | $123,338,680 |
| 2024 | $159,531,149 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II
- Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, et al. · JAMA 2024 · Clinical Trial, Phase III, Comparative Study
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP, Mauro MJ, Cortes JE, et al. · N Engl J Med 2019 · Clinical Trial, Phase I, Multicenter Study
- Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T, Kitaura J, Nakahara F, et al. · Exp Hematol 2014 · Clinical Trial, Multicenter Study
- Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.
Chiaretti S, Piciocchi A, Skert C, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Comparative Study
- A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
Jen WY, Jabbour E, Short NJ, et al. · Am J Hematol 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.